Prevents Pneumocystis jirovecii pneumonia (PCP). ANDA 214272, held by PAI Holdings. Atovaquone.
As of Nov 21, 2026, ANDA 214272 (Atovaquone), held by PAI Holdings, was first approved by FDA on Oct 25, 2021, with 1 approved supplement and 0 published complete response letters.
Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. Limitations of Use: Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2] >45 mm Hg) with atovaquone has not been studied. The efficacy of atovaquone in subjects who are failing therapy with TMP SMX has also not been studied. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML · suspension;oral | Atovaquone | Rx |
| Nov 18, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters